News und Analysen
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) and reminds investors of the June
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3
GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing Lilly to leverage
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Premier Announces the Nation’s 100 Top Hospitals®
Premier, Inc. (NASDAQ: PINC), today announced the nation’s 100 Top Hospitals® with the full list of recognized hospitals published in Fortune®.
To create the list, an objective, quantitative
Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Chemed To Report First-Quarter 2025 Earnings April 23, Related Conference Call To Be Held On April 24
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, following the close of trading on the
EQS-Adhoc: M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
Newron Presents 2024 Financial Results and Provides 2025 Outlook
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Novocure to Report First Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and
Lonza Implements its Simplified and Streamlined Operating Model
EQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company’s Section 382 Rights Agreement (the “Section 382 Rights
Form 8.3 - Advanced Medical Solutions Group PLC - Opening Position Disclosure
ICON plc Schedules First Quarter 2025 Earnings Conference Call
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025
Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss